Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘liver’

Simple CEUS Scan Helps Diagnose Liver Cancer When MRI is Uncertain

Posted by fidest press agency su domenica, 8 settembre 2019

A new study shows that a simple, non-invasive “contrast enhanced ultrasound” (CEUS) scan can be more accurate and reliable than a more expensive MRI procedure for diagnosis of liver tumors and determining whether they are cancerous.The prospective study evaluated 42 patients at high risk for HCC, who were referred for CEUS imaging when their MRI scans over a six-month period, with 24-month follow-ups, were considered indeterminate.“These results significantly impact patients’ treatment and prognosis and reduce time to diagnosis,” Dr. Wilson said.
CEUS can be performed at a fraction of the cost of MRI or CT, and has an excellent, well-established safety profile, according to Dr. Ed Grant, Chair of the Department of Radiology at the University of Southern California Keck Hospital and Treasurer of ICUS.Ultrasound contrast agents are safely and routinely used throughout Canada, Europe, South America and Asia to image organs and tumors throughout the body, as well as to monitor chronic diseases and therapy. Today in the USA, they are FDA-approved for enhancing ultrasound images of the heart and liver in adults and children, but even without FDA approval physicians are permitted to use ultrasound contrast agents for “off-label” imaging when medically indicated. Further, organ-agnostic physician payment codes are now available as of January 1, 2019, Dr. Grant noted. An increasing body of studies now shows that “CEUS is often equivalent or superior to more expensive imaging tools like MR or CT, it allows for dynamic and repeat examinations, and unlike MRI and CT, it can be used in patients with kidney failure or allergy to iodinated contrast agents,” Dr. Wilson said.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer

Posted by fidest press agency su domenica, 4 agosto 2019

Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, today announces that the independent Data Monitoring Committee (“IDMC”) of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis. Sillajen has informed Transgene of the IDMC’s recommendation to stop enrolment in the study, as the study is unlikely to meet its primary objective by the time of the final analysis. SillaJen has not reported safety concerns. Transgene will provide an update in an upcoming conference call.
The PHOCUS trial is a Phase 3 clinical trial evaluating the oncolytic immunotherapy Pexa-Vec for advanced liver cancer patients who have not received prior systemic treatment for their cancer. The study is being conducted by Transgene’s partner, SillaJen.In the PHOCUS study, patients were randomized to one of two treatment groups: one receiving Pexa-Vec followed by sorafenib and one receiving sorafenib alone. The primary objective of the study was to determine the overall survival of patients treated with Pexa-Vec, followed by sorafenib versus sorafenib alone. Secondary objectives included safety as well as assessments for tumor responses between the two groups as measured by the following endpoints: time to progression, progression-free survival, overall response rate and disease control rate.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Leading Liver Cancer Scientific Forum

Posted by fidest press agency su mercoledì, 22 maggio 2019

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the International Liver Cancer Association (ILCA) has accepted Can-Fite’s abstract describing the latest data from the Company’s Phase II Liver Cancer study of Namodenoson for an oral presentation at its annual conference. The oral presentation titled “The Safety and Efficacy of Namodenoson in the Second Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled” will be delivered on September 22, 2019 during the Novel Targets and Prognostic Markers Session from 11:00 am to 12:30 pm. The ILCA’s 13th Annual Conference will take place from September 20 to 22, 2019 in Chicago, Illinois.The ILCA is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines. Its mission is to lead a global community of physicians, scientists and allied professionals through education and research with the goal to better prevent and treat liver cancer.“This is a very prestigious conference that brings together the leading thought leaders, researchers, and physicians in the treatment of liver cancer. Governing members of the ILCA thoroughly research each abstract submission and select those that are most relevant to the advancement of treating liver cancer. We are pleased that the selection committee sees the potential of Namodenoson as a treatment for advanced liver cancer patients with severe liver dysfunction. Based on both safety and efficacy in this Phase II study, Can-Fite is preparing a Phase III trial,” stated Can-Fite CEO Pnina Fishman.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

International Liver Congress™ 2019

Posted by fidest press agency su sabato, 6 aprile 2019

Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter “Shionogi”), announced it will present four posters on lusutrombopag, a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at The International Liver Congress™, the annual meeting of the European Association for the Study of the Liver (EASL), to be held in Vienna, Austria, April 10-14, 2019. Lusutrombopag was granted marketing authorisation by the European Commission (EC) on February 18, 2019 for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing invasive procedures. It has already been approved for use in Japan1 and the US where it is marketed under the brand name Mulpleta®2.All poster presentations will be displayed in Reed Messe Wien Exhibition & Congress Center Hall B on Saturday, April 13, 2019 from 9:00 am to 5:00 pm Central European Time (CET). The research will be presented in the Cirrhosis and Complications poster area and will include the following: Poster SAT 002: Lusutrombopag Is a Safe Treatment Option for Thrombocytopenia in Patients with Chronic Liver Disease Undergoing an Invasive Procedure: Pooled Safety Analysis from 3 Studies.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

New research reveals 4.8% of the UK population have elevated liver iron

Posted by fidest press agency su lunedì, 24 dicembre 2018

The study, conducted by the University of Westminster and Perspectum Diagnostics, used MRI to non-invasively assess levels of liver iron. The numbers of individuals with abnormal levels for two key risk factors of significant liver disease are considerable and represent potentially 2 million NHS patients. The UK health system is under-prepared for the current liver disease epidemic.Iron overload is traditionally associated with genetic disorders such as hereditary haemochromatosis (HH) or as a results of repeated blood transfusions. However elevated levels of liver iron are now often associated with metabolic diseases including insulin resistance, type 2 diabetes and NAFLD. Elevated liver iron is associated with the development of fibrosis and cirrhosis and thought to be involved in the progression from fibrosis to liver cancer.Diagnostic pathways for liver iron currently rely on simple blood tests, which often miss early stages of iron accumulation, and liver biopsy. However, ferritin levels can be influenced by liver damage and inflammation, and in many cases do not correlate well with liver iron stores. Therefore, the development of robust, widely available and non-invasive techniques for the measurement of liver iron are needed. This study used the quantitative MRI behind LiverMultiScan to safely and painlessly assess liver health.Haemochromatosis UK, the national charity representing patients with iron overload, have recently launched an awareness campaign in the House of Commons, and received support from the UK government, the National Consortium of Intelligent Medical Imaging, and GE Healthcare and Perspectum Diagnostics, to improve the availability of MRI scanners with LiverMultiScan and automated image processing to identify NHS patients with iron overload.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Nordion Launches Custom Doses for TheraSphere® Liver Cancer Therapy in Europe and Canada

Posted by fidest press agency su lunedì, 26 marzo 2012

Ottawa, Canada (PRNewswire) Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in Europe and Canada for TheraSphere®, Nordion’s Y-90 microsphere treatment for liver cancer. Nordion has also filed a request with the Food and Drug Administration for approval of the custom dose feature in the United States.In addition to standard dose vial configurations, Nordion now offers an expanded range of TheraSphere treatment options with custom doses available in wider variety of increments. The custom doses are designed to provide greater treatment flexibility for physicians, save administration time and reduce product waste, while limiting unnecessary radiation exposure to patients and healthcare professionals.Nordion has also enhanced its Treatment Window Illustrator tool to demonstrate how custom doses can be selected and compared to standard dose vial configurations.Nordion is attending the Society of Interventional Radiology (SIR) Annual Scientific Meeting 2012, March 24-29, in San Francisco. Nordion representatives will be at Booth #1234 to talk about TheraSphere to physicians attending the conference. Nordion will host two “Eat and Be Educated” learning sessions at its booth:
TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive yttrium-90 (Y-90). The product is injected by physicians into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow. In the US, TheraSphere is used to treat patients with unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and can be used as a bridge to surgery or transplantation in these patients. It is also indicated for the treatment of HCC patients with portal vein thrombosis (PVT). TheraSphere is approved by the U.S Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has more than 500 highly skilled employees in three locations. Find out more at and follow us at

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »